PALB2 pathogenic germline variants are associated with a 7.18, 2.91, and 2.37 RR of developing female breast, ovarian, and pancreatic cancer, respectively, and their estimated incidence up to age 80 years is 53%, 5%, and 2%–3%, respectively [17]. The gene discussed is PALB2; the disease is pancreatic neoplasm.